158 related articles for article (PubMed ID: 35640078)
1. Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
Zhang K; Wang K; Zhang X; Qian Z; Zhang W; Zheng X; Wang J; Jiang Y; Zhang W; Lu Z; Hao H; Jiang S
J Med Chem; 2022 Jun; 65(11):7746-7769. PubMed ID: 35640078
[TBL] [Abstract][Full Text] [Related]
2. Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase.
Song J; Zou G; Zhao Z; Zhu Y; Xue J; Ao L; Sun H; Hao H; Zhang B; Xu X
Chin J Nat Med; 2024 Jan; 22(1):75-88. PubMed ID: 38278561
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
[TBL] [Abstract][Full Text] [Related]
4. NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells.
Liu HY; Li QR; Cheng XF; Wang GJ; Hao HP
Chin J Nat Med; 2016 Aug; 14(8):582-9. PubMed ID: 27608947
[TBL] [Abstract][Full Text] [Related]
5. Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer.
Wang K; Ye K; Zhang X; Wang T; Qi Z; Wang Y; Jiang S; Zhang K
J Med Chem; 2023 Jan; 66(1):1027-1047. PubMed ID: 36595482
[TBL] [Abstract][Full Text] [Related]
6. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
[TBL] [Abstract][Full Text] [Related]
7. NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer.
Madajewski B; Boatman MA; Martinez I; Carter JH; Bey EA
Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980879
[TBL] [Abstract][Full Text] [Related]
8. Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis.
Yu J; Zhong B; Zhao L; Hou Y; Ai N; Lu JJ; Ge W; Chen X
Drug Resist Updat; 2023 Sep; 70():100977. PubMed ID: 37321064
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
[TBL] [Abstract][Full Text] [Related]
10. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
11. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
13. 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
Zhang X; Bian J; Li X; Wu X; Dong Y; You Q
Eur J Med Chem; 2017 Sep; 138():616-629. PubMed ID: 28710963
[TBL] [Abstract][Full Text] [Related]
14. Antioxidative enzyme NAD(P)H quinone oxidoreductase 1 (NQO1) modulates the differentiation of Th17 cells by regulating ROS levels.
Nishida-Tamehiro K; Kimura A; Tsubata T; Takahashi S; Suzuki H
PLoS One; 2022; 17(7):e0272090. PubMed ID: 35905076
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
16. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
18. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
Zhang K; Chen D; Ma K; Wu X; Hao H; Jiang S
J Med Chem; 2018 Aug; 61(16):6983-7003. PubMed ID: 29712428
[TBL] [Abstract][Full Text] [Related]
20. Deoxynyboquinones as NQO1-Activated Cancer Therapeutics.
Parkinson EI; Hergenrother PJ
Acc Chem Res; 2015 Oct; 48(10):2715-23. PubMed ID: 26444384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
